Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report. This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD.
